Development of Novel Injectable and Inhaled Cannabinoid Drugs for Systemic Inflammation and ARDS

Time: 9:00 am
day: Day Two


• Evidence supporting the Cannabinoid Type 2 receptor (CB2) as an important immunemodulatory target
• Challenges, successes and caveats in the development and positioning of Cannabinoid Therapeutics for Systemic Inflammation
• Bridging the gap between systemic and inhaled cannabinoids for ARDS